Last reviewed · How we verify

NCT07231588

Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation

Recruiting now EARLY_PHASE1 Last updated 5 February 2026
What this trial tests

EARLY_PHASE1 trial testing Pendulum Glucose Control (PGC) in Radiation Injuries in 20 participants. Currently enrolling.

Timeline
29 January 2026
Primary endpoint
29 June 2026
29 December 2026

Quick facts

Lead sponsorUniversity of Cincinnati
PhaseEARLY_PHASE1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment20
Start date29 January 2026
Primary completion29 June 2026
Estimated completion29 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Cincinnati

Who can join

18 and older, any sex, with Radiation Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is to determine if an oral probiotic, Pendulum Glucose Control (PGC), can be safely given to patients during pelvic radiation therapy (RT). The researchers will study if the probiotics lessen gastrointestinal toxicity during pelvic radiation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Radiation Injuries

Currently open trials in the same condition.

Other University of Cincinnati trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07231588.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing